Optipharm Co., Ltd. (153710) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Optipharm Co., Ltd. (153710:KRX), powered by AI.

Current Price
₩4,670
P/E Ratio
-27.4
Market Cap
68.5B
Sector
Healthcare
What is the Optipharm Co., Ltd. stock price forecast?

Optipharm Co., Ltd. is currently trading at ₩4,670. View real-time AI analysis on Alpha Lenz.

What is Optipharm Co., Ltd. insider trading activity?

View the latest insider trading data for Optipharm Co., Ltd. on Alpha Lenz.

What is Optipharm Co., Ltd.'s P/E ratio?

Optipharm Co., Ltd.'s P/E ratio is -27.4.

Optipharm Co., Ltd.

KRX · 153710
₩4,670+35(+0.76%)Market closedKRX regular session 09:00–15:30 KST
Ask about Optipharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Optipharm Co., Ltd. trades at a P/E of -27.4 (undervalued) with modest ROE of -9.5%. 3Y revenue CAGR of 11.8% highlights clear growth momentum.

Ask for details

Company Overview

Optipharm Co., Ltd. operates as a pharmaceutical company primarily engaged in the development, production, and distribution of healthcare and pharmaceutical products. It focuses on producing a wide array of medications and health-related supplements aimed at improving patient health and meeting diverse medical needs. The company plays a crucial role in the healthcare industry, providing innovative solutions that cater to a broad spectrum of health conditions. Optipharm Co., Ltd. is committed to research and development, ensuring it stays at the forefront of medical advancements. By maintaining stringent quality controls and regulatory compliance, the company assures the efficacy and safety of its products. In the financial markets, Optipharm Co., Ltd. holds significance as part of the pharmaceutical sector, often attracting attention from stakeholders interested in the health and biotechnological advancements. Its impact extends to various segments, including hospitals, pharmacies, and direct patient care, emphasizing its importance within the supply chain. Overall, Optipharm Co., Ltd. reflects the ongoing global demand for reliable health solutions and positions itself as an integral player in advancing public health initiatives.

CEO김현일
SectorHealthcare
IndustryDiagnostics & Research
0

Company Statistics

FY 2025

Profile

₩68,508,703,860Market Cap
₩22,344,530,940Revenue
14.67MShares Out
0Employees

Margins

25.02%Gross
-1.36%EBITDA
-10.80%Operating
-11.18%Pre-Tax
-11.18%Net

Valuation

-27.41P/E
2.70P/B
3.07EV/Sales
-251.92EV/EBITDA
-16.71P/FCF

Growth (CAGR)

11.76%Rev 3Yr
11.36%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-5.94%ROA
-9.48%ROE
-4.75%ROIC

Financial Health

₩2,276,860,510Cash & Cash Equivalents
₩13,092,053,770Net Debt
60.51%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Optipharm Co., Ltd. (ticker: 153710) is a company listed on KRX in the Healthcare sector (Diagnostics & Research). Market cap is $68.5B.

The current price is ₩4,670 with a P/E ratio of -27.41x and P/B of 2.7x.

ROE is -9.48% and operating margin is -10.80%. Annual revenue is $22.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Optipharm Co., Ltd. (153710) Stock Forecast 2026 ₩4,670 — Price, Financials & Analyst Targets | Alpha Lenz